• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

Best Read Articles on Safety Issues and Recalls in 2021


News about counterfeit versions of Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) and Descovy (emtricitabine, tenofovir alafemamide) and the pause in the REMS program for clozapine were among the best read articles of 2021.

Apotex to Import Generic of Chantix from Canada

This is being done in coordination with the FDA to address the shortage created by the recall of Chantix. UPDATE: Pfizer has expanded its recall of Chantix from nine lots to 12 lots.

Read more

Counterfeit Versions of Biktarvy and Descovy Found in Pharmacies

The bottles have a counterfeit foil seal or label and contain an incorrect number of tablets.

Read more

FDA’s New Warning Includes Xeljanz and other JAK Inhibitors

The FDA’s review of the JAK inhibitor class concluded there is an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death with these arthritis and ulcerative colitis medicines.

Read more

FDA Pauses Clozapine REMS Program

New requirements resulted in long call wait times, which has led to patient access issues.

Read more

Piqray’s Safety Label is Updated

Some fatal cases of ketoacidosis have occurred, and high-risk patients should be monitored when starting treatment.

Read more

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.